DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Priority
Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55.
Information Disclosure Statement
The information disclosure statement (IDS) submitted on March 25, 2025; June 25, 2025 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.
Drawings
The drawings filed on March 25, 2025 are accepted.
Claim Objections
Claims 2-5, 9-13 and 15 are objected to because of the following informalities:
Claims 2 and 10 recite “photoplethsmography” should read “photoplethysmography” missing the middle y.
Claim 2-5 and 9-13 recites, “EMG”, “ECG”, “E-nose”, “EOG”, “PSG” are not properly defined. The full spelling should be followed by the abbreviation in parenthesis, like how “CPAP” was first introduced in the claim. “PSG” is not defined in claim 5.
Appropriate correction is required.
Claim Interpretation
The following is a quotation of 35 U.S.C. 112(f):
(f) Element in Claim for a Combination. – An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof.
The following is a quotation of pre-AIA 35 U.S.C. 112, sixth paragraph:
An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof.
The claims in this application are given their broadest reasonable interpretation using the plain meaning of the claim language in light of the specification as it would be understood by one of ordinary skill in the art. The broadest reasonable interpretation of a claim element (also commonly referred to as a claim limitation) is limited by the description in the specification when 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is invoked.
As explained in MPEP § 2181, subsection I, claim limitations that meet the following three-prong test will be interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph:
(A) the claim limitation uses the term “means” or “step” or a term used as a substitute for “means” that is a generic placeholder (also called a nonce term or a non-structural term having no specific structural meaning) for performing the claimed function;
(B) the term “means” or “step” or the generic placeholder is modified by functional language, typically, but not always linked by the transition word “for” (e.g., “means for”) or another linking word or phrase, such as “configured to” or “so that”; and
(C) the term “means” or “step” or the generic placeholder is not modified by sufficient structure, material, or acts for performing the claimed function.
Use of the word “means” (or “step”) in a claim with functional language creates a rebuttable presumption that the claim limitation is to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites sufficient structure, material, or acts to entirely perform the recited function.
Absence of the word “means” (or “step”) in a claim creates a rebuttable presumption that the claim limitation is not to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is not interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites function without reciting sufficient structure, material or acts to entirely perform the recited function.
Claim limitations in this application that use the word “means” (or “step”) are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. Conversely, claim limitations in this application that do not use the word “means” (or “step”) are not being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action.
This application includes one or more claim limitations that do not use the word “means,” but are nonetheless being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, because the claim limitation(s) uses a generic placeholder that is coupled with functional language without reciting sufficient structure to perform the recited function and the generic placeholder is not preceded by a structural modifier.
Such claim limitation(s) is/are:
Claim 1: Claim limitation “a stroke onset detection module” has been interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, because it uses a generic placeholder “unit” coupled with functional language “for identifying an onset of stroke” without reciting sufficient structure to achieve the function. Furthermore, the generic placeholder is not preceded by a structural modifier that has a known structural meaning before the phrase “unit”.
Claim 1: Claim limitation “a stroke onset alert module” has been interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, because it uses a generic placeholder “unit” coupled with functional language “for outputting a stroke onset alert signal” without reciting sufficient structure to achieve the function. Furthermore, the generic placeholder is not preceded by a structural modifier that has a known structural meaning before the phrase “unit”.
Because this/these claim limitation(s) is/are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, it/they is/are being interpreted to cover the corresponding structure described in the specification as performing the claimed function, and equivalents thereof.
A review of the specification shows that the following appears to be the corresponding structure described in the specification for the 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph limitation:
Claim 1: “a stroke onset detection module” and “a stroke onset alert module” refers to the specification page 9 discussing computer components. Therefore the modules is interpreted as a processor, along with the instructions/algorithm for performing the corresponding functions as described in the specification.
If applicant does not intend to have this/these limitation(s) interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, applicant may: (1) amend the claim limitation(s) to avoid it/them being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph (e.g., by reciting sufficient structure to perform the claimed function); or (2) present a sufficient showing that the claim limitation(s) recite(s) sufficient structure to perform the claimed function so as to avoid it/them being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph.
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
Claims 1-3, 6-13 and 16-20 are rejected under 35 U.S.C. 103 as being unpatentable over Mumford et al. (US 2007/0208269 A1) (“Mumford”) in view of Grashow (US 11,844,898 B2) (“Grashow”) in further view of Vardoulis et al. (US 2025/0169768 A1) (“Vardoulis”).
Regarding claims 1 and 8, Mumford discloses A method for stroke onset alert for a continuous positive airway pressure (CPAP) system, the method comprising (Abstract and entire document):
providing, via a blower, a pressurized flow of breathable gas to a patient interface device being worn by a subject during delivery of the pressurized flow of breathable gas, via a patient circuit fluidly coupled between the blower and the patient interface device (FIG. 1 and at least [0055], “a CPAP system 10 including a mask assembly 12 and a CPAP device 14 with an associated monitoring unit 16 for use by a CPAP device wearer 18… The mask assembly 12 also includes a gas inlet 28 for receiving air, or another suitable gas such as pure oxygen, from the CPAP device 14 via a hose 30.”);
monitoring and recording, via a monitoring unit integral with the patient interface device, a predetermined set of vital signs and physical symptoms of the subject relating to an onset of acute stroke attack or stroke episode (FIG. 1 and at least [0055 - 60], “sensors 32”, “monitoring unit 16”, integral sensors part of the mask detect vital signs relating to stroke);
identifying, via a stroke onset detection module, an onset of stroke based on an analysis of the monitored and recorded set of vital signs and physical symptoms (FIG. 1 and at least [0147], “Embodiments may also be used within the context of an intensive care unit (ICU), for example to assist in detection of a seizure, stroke, ischemia, burst-suppression or brain hemorrhage or for use in determining a level of consciousness, sedation or delirium of a patient.”); and
Mumford fails to disclose outputting, via a stroke onset alert module, a stroke onset alert signal based on the identification of the onset of stroke via the stroke onset detection module,
wherein the monitoring unit comprises a plurality of sensors for implementing one or more series of sensor modalities for determination of at least heart rate variability, heart rate and arrythmias.
However, in the same field of endeavor, Grashow teaches outputting, via a stroke onset alert module, a stroke onset alert signal based on the identification of the onset of stroke via the stroke onset detection module (Col. 9 lines 16-47),
It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention, to modify the system/method as taught by Mumford to include outputting, via a stroke onset alert module, a stroke onset alert signal based on the identification of the onset of stroke via the stroke onset detection module, as taught by Grashow to alert a caregiver (Col. 9 lines 16-47).
Mumford as modified fails to disclose wherein the monitoring unit comprises a plurality of sensors for implementing one or more series of sensor modalities for determination of at least heart rate variability, heart rate and arrythmias.
However, in the same field of endeavor, Vardoulis teaches wherein the monitoring unit comprises a plurality of sensors for implementing one or more series of sensor modalities for determination of at least heart rate variability, heart rate and arrythmias ([0046], “ECG”, “HRV”).
It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention, to modify the system/method as taught by Mumford to include wherein the monitoring unit comprises a plurality of sensors for implementing one or more series of sensor modalities for determination of at least heart rate variability, heart rate and arrythmias as taught by Vardoulis to assist in stroke detection monitoring multi-factor consideration ([0046]).
Regarding claims 2 and 9-11, Mumford as modified discloses The method of claim 1, Mumford as modified further discloses wherein the plurality of sensors are selected from the group consisting of photoplethsmography PPG sensors, EMG sensors, ECG sensors, and E-nose sensors, wherein the PPG sensors are integrated in different places of the patient interface device, wherein the EMG sensors are integrated in different places in the patient interface device that include a mask portion and a headgear strap portion, further wherein the EMG sensors are adapted (i) to detect muscle tension in a predetermined number of places on the subject's face, (ii) to detect and distinguish muscle weakness and muscle atonia, and (iii) to enable a comparison of muscle tension on both sides of the subject's face based on a determination of individual differences and individual thresholds (Mumford [0058], “EEG, EMG, EOG”; Vardoulis [0046], ECG, EEG,), and
wherein the ECG sensors are integrated in different places of the patient interface device, further wherein the ECG sensors are adapted to determine heart rate variability HRV and HRV changes, and wherein an HRV decease is associated with acute stroke severity (Vardoulis [0046], “ECG”, “HRV”).
Regarding claims 3 and 12, Mumford as modified discloses The method of claim 1, Mumford as modified further discloses wherein the plurality of sensors includes at least one of (i) a breath pattern sensor modality adapted for determination of brain hypoxia based on a breathing pattern of the subject, or (ii) electronic nose, E-nose, sensors adapted for breath analysis and a determination of volatile markers and a given concentration linked to a moment of stroke onset (Grashow Col. 9 lines 3-15).
Regarding claim 13, Mumford as modified discloses The system of claim 8, Mumford as modified further discloses wherein the plurality of sensors includes sensor modalities of EOG sensors and EEG sensors, wherein the EOG sensors are integrated in the patient interface device to detect a lateralized asymmetry of the subject's face, and wherein the EEG sensors are adapted for monitoring progressive changes in EEG morphology amplitude, and frequency that correlate with a severity of stroke (Mumford FIG. 1 and [0058]).
Regarding claims 6 and 16, Mumford as modified discloses The method of claim 1, Mumford as modified further discloses wherein the stroke onset detection module comprises a dedicated algorithm to process and analyze the monitored and recorded set of vital signs and physical symptoms for identification of a presence of the onset of the acute stroke attack or stroke episode, and wherein the monitored and recorded set includes at least measured physical symptoms and hemodynamic and respiratory parameters (Vardoulis [0027]).
Regarding claims 7 and 17, Mumford as modified discloses The method of claim 1, Mumford as modified further discloses wherein the stroke onset detection module is configured to use machine learning or predictive modeling algorithms for the analysis of the monitored and recorded set of vital signs and physical symptoms to identify the onset of stroke (Vardoulis [0027]).
Regarding claim 18, Mumford as modified discloses The system of claim 8, Mumford as modified further discloses wherein the stroke onset alert signal comprises at least one of (i) a warning signal configured to carry out one or more of (a) alert the subject, (b) alert someone other than the subject, and (c) initiate an emergency call to a medical provider, emergency medical personnel, or rescue team, or (ii) one or more of a tactile, visual, and auditory alert for signaling an occurrence of the onset of stroke (Grashow Col. 9 lines 16-47).
Regarding claims 19, Mumford as modified discloses The system of claim 8, Mumford as modified further discloses wherein the stroke onset alert signal further comprises a follow-up information signal for use in seeking additional information, wherein the follow-up information signal is communicated to a remote audio-visual display device based on a given level of uncertainty in a prediction of the onset of stroke based on the identified onset of stroke (Grashow Col. 9 lines 16-47).
Regarding claim 20, Mumford as modified discloses A patient interface adapted to be used in the CPAP system of claim 8, wherein the patient interface comprises the monitoring unit (Mumford FIG. 1 and at least [0055 - 60], “sensors 32”, “monitoring unit 16”, integral sensors part of the mask detect vital signs relating to stroke).
Claims 4 and 14 are rejected under 35 U.S.C. 103 as being unpatentable over Mumford in view of Grashow in further view of Vardoulis in further view of Lim et al. (US 2018/0125386 A1) (“Lim”).
Regarding claims 4 and 14, Mumford as modified discloses The method of claim 1, wherein the plurality of sensors includes at least one of (i) sensor modalities of EOG sensors and EEG sensors, wherein the EOG sensors are integrated in the patient interface device to detect a lateralized asymmetry of the subject's face, and wherein the EEG sensors are adapted for monitoring progressive changes in EEG morphology amplitude, and frequency that correlate with a severity of stroke (Mumford FIG. 1 and [0058]), or
Mumford as modified fails to disclose (ii) a facial camera integrated in the patient interface device and adapted for use in detecting stroke onset based on a positioning of the subject's head and features of the subject's face, or
(iii) simultaneous use of stimulating and recording electroneurography ENoG electrodes integrated in the patient interface device and adapted for use in detecting stroke onset.
However, in the same field of endeavor, Lim teaches (ii) a facial camera integrated in the patient interface device and adapted for use in detecting stroke onset based on a positioning of the subject's head and features of the subject's face ([0209]), or
(iii) simultaneous use of stimulating and recording electroneurography ENoG electrodes integrated in the patient interface device and adapted for use in detecting stroke onset ([0187]).
It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention, to modify the system/method as taught by Mumford to include (ii) a facial camera integrated in the patient interface device and adapted for use in detecting stroke onset based on a positioning of the subject's head and features of the subject's face, or (iii) simultaneous use of stimulating and recording electroneurography ENoG electrodes integrated in the patient interface device and adapted for use in detecting stroke onset as taught by Lim for additional information in the consideration ([0187]).
Claims 5 and 15 are rejected under 35 U.S.C. 103 as being unpatentable over Mumford in view of Grashow in further view of Vardoulis in further view of Ferriera Dos Santos Da Fonseca et al. (US 2020/0093422 A1) (“Ferriera”).
Regarding claims 5 and 15, Mumford as modified discloses The method of claim 1, Mumford as modified fails to disclose wherein the plurality of sensors includes ambulatory PSG sensors adapted for detecting sleep stages and apnea events.
However, in the same field of endeavor, Ferriera teaches wherein the plurality of sensors includes ambulatory PSG sensors adapted for detecting sleep stages and apnea events ([0044], “PSG”).
It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention, to modify the system/method as taught by Mumford to include wherein the plurality of sensors includes ambulatory PSG sensors adapted for detecting sleep stages and apnea events as taught by Ferriera to use the gold standard ([0044]).
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to JOSEPH A TOMBERS whose telephone number is (571)272-6851. The examiner can normally be reached on M-TH 7:00-16:00, F 7:00-11:00(Eastern).
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert Chen can be reached on 571-272-3672. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see https://ppair-my.uspto.gov/pair/PrivatePair. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/JOSEPH A TOMBERS/ Examiner, Art Unit 3791